Clinical trials
PET clinical trials
Below are recruiting pet clinical trials, each written for real people, not researchers. We’re tracking 590 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07110519RecruitingEarly Phase 1
PET scan safety study with [18F]-Fluoromannitol in healthy volunteers
This study tests a new radioactive tracer called [18F]-Fluoromannitol for PET scans in healthy adults. It checks how the tracer moves in the body and if it's safe.
Memphis, TennesseeAges 18–75 - NCT07115017Recruiting
Testing a new PET scan tracer for brain inflammation in MS
This study uses a new radioactive tracer called [18F]-FZTA during a PET scan to see inflammation in the brain. Researchers want to test this tracer in both healthy adults and people with multiple sclerosis (MS) to see if it can help detect MS activity.
St Louis, MissouriAges 18 years+ - NCT07115238RecruitingPhase 3
PET imaging study for normal aging, MCI, and Alzheimer's
This trial tests a new PET imaging agent (18F-XTR006) to see how well it shows brain changes related to Alzheimer's disease. It may help diagnose MCI (mild cognitive impairment) or Alzheimer's earlier by comparing images in healthy people and those with memory problems.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07116486RecruitingPhase 1
Using a new PET scan to guide liver cancer treatment
This trial tests a special PET scan (18F-FSPG) to help guide therapy for people with liver cancer (HCC) who are planning to receive Y90 radioembolization. The scan may help doctors better plan your treatment.
Houston, TexasAges 18 years+ - NCT07122674Recruiting
New PET scan for blood cancers
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
Hangzhou, ZhejiangAges 18–80 - NCT07131475RecruitingPhase 2
Brain injury detection in Navy SEALs with blast exposure
This study looks for early signs of brain injury in Navy SEALs who are repeatedly exposed to blasts. It uses advanced scans and biomarkers to find changes that might lead to problems later on.
Boston, MassachusettsAges 18–50 - NCT07144085RecruitingPhase 1
Testing a new PET scan tracer for cancer diagnosis
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
Shenyang, LiaoningAges 18–80 - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07159607Recruiting
PET scan for IDH-mutant brain tumors
This trial uses a special PET scan to see how IDH-mutant gliomas respond to treatment. It may help your doctor better track your tumor's activity.
ViennaAges 18 years+ - NCT07207798Recruiting
Epidural spinal stimulation for spinal cord injury (T11-L3)
This trial tests whether epidural electrical stimulation can help people with spinal cord injury between T11 and L3 improve their walking ability. It is for those injured between 2 and 24 months ago who currently have limited walking function.
Hangzhou, ZhejiangAges 16–65 - NCT07209059RecruitingPhase 2
Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
MoscowAges 18–60 - NCT07209878RecruitingPhase 2/Phase 3
PET scan vs. MRI for prostate cancer diagnosis
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
Fuzhou, FujianAges 18–80 - NCT07210086RecruitingPhase 2
PET scans to guide radiation for limited metastatic prostate cancer
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Duarte, CaliforniaAges 18 years+ - NCT07217028RecruitingPhase 1
Safety study of a new PET tracer for head and neck cancer
This study tests a new radioactive tracer called [18F]NOTA-ABY030 to see if it's safe for people with head and neck cancer that may have spread. The tracer lights up cancer cells on a PET scan, helping doctors find tumors more clearly.
Nashville, TennesseeAges 18 years+ - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07220720RecruitingPhase 2
PET scan for suspicious prostate spots before biopsy
This trial tests whether a special PET scan (called POSLUMA) can help find prostate cancer earlier in men who have an MRI showing a suspicious spot (PIRADS 2 or 3) but haven't yet had a biopsy. If you are scheduled for a biopsy, this scan may give your doctor extra information before the procedure.
Jacksonville, FloridaAges 18–100 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT07234487RecruitingPhase 2
Comparing two drug combos for advanced Hodgkin lymphoma
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
MoscowAges 18–60 - NCT07234981RecruitingPhase 2
Using PSMA-PET to guide less intense radiation for returning prostate cancer
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Omaha, NebraskaAges 30 years+ - NCT07235709Recruiting
Study of agalsidase alfa for heart inflammation in Fabry disease
This trial tests whether agalsidase alfa can reduce heart inflammation in people with Fabry disease who have heart problems. You may qualify if you have not had this treatment in the past year.
SeoulAges 15–75 - NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+
Hear when a new PET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pet?
- Yes. Clin2 currently lists 590 recruiting pet studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pet trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pet trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.